Monitor WW's future earnings reports for Med+ membership growth trends and any update on partnership-driven revenue. While this improves patient affordability, it does not directly boost WW's top line unless it translates into higher enrollment or retention.
Price Chart
Executive Summary
WW International announced an expanded collaboration with Novo Nordisk to offer eligible Med+ members discounted subscription pricing for Wegovy, saving up to $1,200 annually. This enhances access to GLP-1 treatment and reinforces WW's integrated weight health model, though no financial impact on revenue or profitability was quantified.
Key Facts
- WW International and Novo Nordisk expanded their collaboration to offer subscription pricing for Wegovy to eligible Med+ members.
- Members can save up to $1,200 per year, or up to $100/month on pens and $50/month on pills, via pre-paid 3, 6, or 12-month plans.
- The offer applies to all Wegovy pen doses and 9 mg/25 mg pill doses; existing limited-time offers also remain available.
- WW is a NovoCare® Recognized Care Provider and emphasizes combining medication with lifestyle support for better outcomes.
- No financial terms, revenue impact, or membership uptake figures were disclosed.
Financial Impact
No direct financial impact disclosed; potential indirect benefit from increased Med+ membership demand.
Risk Factors
- No material financial benefit if increased access does not drive higher Med+ adoption.
- Dependence on Novo Nordisk's supply and pricing policies, which are outside WW's control.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265364 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $14.94 $15.44 | ▲ +3.35% | ▲ +4.44% | $15.05 (+0.74%) |
Aug 20, 2026 6w ago | Insider Buy | $15.71 $16.20 | ▲ +3.12% | ▲ +2.65% | $15.05 (−4.20%) |
Jul 23, 2026 10w ago | Press Release | $13.34 $13.90 | ▲ +4.20% | ▲ +3.82% | $15.05 (+12.82%) |
Jun 16, 2026 15w ago | Press Release | $19.05 $17.55 | ▼ −7.87% | ▼ −6.83% | $15.05 (−21.00%) |
Jun 4, 2026 17w ago | DEFA14A | $17.27 $19.58 | ▲ +13.41% | ▲ +15.96% | $15.05 (−12.83%) |
May 27, 2026 18w ago | Insider Cluster | $17.10 $16.13 | ▼ −5.67% | ▼ −5.62% | $15.05 (−11.99%) |
May 15, 2026 19w ago | DEFA14A | $10.03 $13.84 | ▲ +37.99% | ▲ +36.37% | $15.05 (+50.05%) |
Apr 27, 2026 22w ago | 8-K | $10.51 $10.91 | ▲ +3.81% | ▲ +3.41% | $15.05 (+43.20%) |
Apr 23, 2026 23w ago | Press Release | $9.27 $10.53 | ▲ +13.59% | ▲ +12.68% | $15.05 (+62.35%) |
Apr 20, 2026 23w ago | 8-K | $10.00 $10.51 | ▲ +5.10% | ▲ +4.19% | $15.05 (+50.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access